First Oncological Veterinary Patient Now Cancer Free after Treatment with Theraclion’s Echopulse®

  • A veterinary study at the Virginia-Maryland College of Veterinary Medicine, financed by the Focused Ultrasound Foundation, was launched in November

MALAKOFF, France--()--Regulatory News:

THERACLION (Alternext, FR0010120402 – ALTHE) (Paris:ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today that a first canine cancer patient is now cancer free after treatment by Theraclion’s Echopulse®.

A veterinary study at the Virginia-Maryland College of Veterinary Medicine (VMCVM) at Virginia Tech in Blacksburg, Virginia, financed by the Focused Ultrasound Foundation, is currently investigating the treatment of dogs with sarcomas and mast cell tumors with Echopulse® which is rented for a research program.

Echopulse® is Theraclion’s non-invasive focused ultrasound solution. It originally was designed to ablate human tumors and is currently CE marked for the use in breast fibroadenomas and benign thyroid nodules. However, its unique robotic design allows it to easily be adapted for veterinary indications.

“These canine tumors tend to occur on the limbs and may recur if they are not entirely removed. As a result, often amputation is required,” said Dr. Ruth, Clinical Assistant Professor of Radiology at VWCVM. “It is our hope that focused ultrasound will add to current treatment options by providing a way to non-invasively ablate the mass and also trigger an anti-tumor immune response.”

The canine study is only one of several studies launched by the Focused Ultrasound Foundation in their veterinary program to develop focused ultrasound therapies for the treatment of companion animals.

The global pet cancer therapeutics market was valued at US$ 183.3 million in 2017 and is expected to witness a robust CAGR of 7.7% over the forecast period (2017 - 2025). Increasing number of research grants to launch various anti-cancer therapies for veterinary cancer treatment is expected to be a major factor driving growth of the global pet cancer therapeutics market in near future. 1

“As veterinary treatments are a pure out-of-pocket market, “patient” access to innovation is sometimes much faster than for humans. The trial results will be on the one hand beneficial for the veterinary patients and on the other hand provide additional proof of feasibility for cancer treatments in human applications,” adds David Caumartin, CEO of Theraclion.

1 https://www.coherentmarketinsights.com/market-insight/pet-cancer-therapeutics-market-1284

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 35 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com

Theraclion is listed on Euronext Growth Paris
PEA-PME eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

Contacts

Theraclion
David Caumartin, Tel.: +33 (0)1 55 48 90 70
CEO
david.caumartin@theraclion.com
or
Anja Kleber, Tél.: + 33 (0)6 07 95 44 39
VP Marketing, Market Access & Sales Francophonia
anja.kleber@theraclion.com

Contacts

Theraclion
David Caumartin, Tel.: +33 (0)1 55 48 90 70
CEO
david.caumartin@theraclion.com
or
Anja Kleber, Tél.: + 33 (0)6 07 95 44 39
VP Marketing, Market Access & Sales Francophonia
anja.kleber@theraclion.com